1496-78-2

Usage

Uses

Used in Pharmaceutical Research and Development:
3-Bromo-2-methyl-1H-indole is used as a building block for the synthesis of organic compounds, particularly in the development of new pharmaceuticals. Its unique structure and potential biological activities make it a valuable component in the creation of novel drug candidates.
Used in Antimicrobial Applications:
3-Bromo-2-methyl-1H-indole is used as an antimicrobial agent, exhibiting activity against various types of bacteria. Its potential use in this area is currently being studied, with the aim of developing new treatments for bacterial infections.
Used in Antiviral Applications:
3-Bromo-2-methyl-1H-indole is also being investigated for its potential as an antiviral agent, with research focusing on its ability to inhibit the replication of certain viruses. This could lead to the development of new antiviral medications in the future.
Used in Chemical Reactions:
3-Bromo-2-methyl-1H-indole is used as a versatile tool in chemical reactions, allowing for the preparation of diverse molecular structures. Its ability to undergo various reactions makes it a valuable component in the synthesis of a wide range of organic compounds.

Upstream product

• 95-20-5 2-methyl-1H-indole 

Downstream Products

• 88919-88-4 2',3-Dimethyl-2,3'-bi-indolyl 
• 177274-66-7 1-phenylsulfonyl-3-bromo-2-methylindole 
• 177274-68-9 N-((3-bromo-1-(phenylsulfonyl)-1H-indol-2-yl)methyl)benzenesulfonamide 
• 177274-70-3 N-allyl-N-((3-bromo-1-(phenylsulfonyl)-1H-indol-2-yl)methyl)benzenesulfonamide 
• 95-20-5 2-methyl-1H-indole 
• 1542705-49-6 N-benzyl-2-(2-methyl-1H-indol-3-yl)-5,6,7,8-tetrahydroquinazolin-4-amine 
• 1627721-62-3 tert-butyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate 
• 1558050-11-5 C₂₉H₂₆N₂O₄ 
• 1558050-10-4 C₂₈H₂₄N₂O₃ 
• 80360-21-0 1-(benzenesulfonyl)-2-methyl-1H-indole 
• 1297280-93-3 2-(3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methyl-1H-indol-1-yl)acetic acid 
• 1297285-52-9 tert-butyl 2-(3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methyl-1H-indol-1-yl)acetate 

Relevant academic research and scientific papers

Catalyst-Free 1,2-Dibromination of Alkenes Using 1,3-Dibromo-5,5-dimethylhydantoin (DBDMH) as a Bromine Source

A direct 1,2-dibromination method of alkenes is realized using 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) as a bromine source. This reaction proceeds under mild reaction conditions without the use of a catalyst and an external oxidant. Various sorts of alkene substrates are transformed into the corresponding 1,2-dibrominated products in good to excellent yields with broad substrate scope and exclusive diastereoselectivity. This method offers a green and practical approach to synthesize vicinal dibromide compounds.

Photoinduced Skeletal Rearrangement of Diarylethenes: Photorelease of Lewis Acid and Synthetic Applications

The skeletal photorearrangement including 6π-electrocyclization induced by UV light ofortho-halogen-substituted diarylethenes has been studied. It has been found that the reaction pathways leading to bi- or tricyclic frameworks depend on the kind of halog

Predicting the Substrate Scope of the Flavin-Dependent Halogenase BrvH

The recently described flavin-dependent halogenase BrvH is able to catalyse both the bromination and chlorination of indole, but shows significantly higher bromination activity. BrvH was annotated as a tryptophan halogenase, but does not accept tryptophan as a substrate. Its native substrate remains unknown. A predictive model with the data available for BrvH was analysed. A training set of compounds tested in vitro was docked into the active site of a complete protein model based on the X-ray structure of BrvH. The atoms not resolved experimentally were modelled by using molecular mechanics force fields to obtain this protein model. Furthermore, docking poses for the substrates and known non-substrates have been calculated. Parameters like distance, partial charge and hybridization state were analysed to derive rules for predicting activity. With this model for activity of the BrvH, a virtual screening suggested several structures for potential substrates. Some of the compounds preselected in this way were tested in vitro, and several could be verified as convertible substrates. Based on information on halogenated natural products, a new dataset was created to specifically search for natural products as substrates/products, and virtual screening in this database yielded further hits.

SEROTONIN 5-HT2B INHIBITORY COMPOUNDS

The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably c

Preparation method of diaryl heterocycle substituted hexafluorocyclopentene-based photochromic compound

The invention relates to a preparation method of a diaryl heterocycle substituted hexafluorocyclopentene-based photochromic compound, and belongs to an organic photochromic material. The preparation method comprises: 1, synthesizing 5-methyl-4-bromo-2-thiophene formaldehyde diethanol; 2, synthesizing 1,2-dimethyl-5-R1-3-bromoindole; and 3, synthesizing a diaryl heterocycle substituted hexafluorocyclopentene-based photochromic compound. According to the present invention, the prepared diaryl heterocycle substituted hexafluorocyclopentene-based photochromic compound has the red shift of the absorption wavelength of 50-100 nm, is a thermally-irreversible bistable state, and can be used in the fields of optical information storage, anti-counterfeiting recognition, concealing materials and military camouflage materials.

Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3

Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. Herein, we report the identification and subsequent optimi

Atom-Economic Electron Donors for Photobiocatalytic Halogenations

In vitro cofactor supply and regeneration have been a major obstacle for biocatalytic processes, in particular on a large scale. Peroxidases often suffer from inactivation by their oxidative co-factor. Combining photocatalysis and biocatalysis offers an innovative solution to this problem, but lacks atom economy due to the sacrificial electron donors needed. Herein, we show that redox-active buffers or even water alone can serve as efficient, biocompatible electron sources, when combined with photocatalysis. Mechanistic investigations revealed first insights into the possibilities and limitations of this approach and allowed adjusting the reaction conditions to the specific needs of biocatalytic transformations. Proof-of-concept for the applicability of this photobiocatalytic reaction setup was given by enzymatic halogenations.

Simple and efficient procedures for selective preparation of 3-haloindoles and 2,3-dihaloindoles by using 1,3-dibromo-5,5-dimethylhydantoin and 1,3-dichloro-5,5-dimethylhydantoin

Simple and efficient synthetic procedures for the selective preparation of 3-bromo/3-chloroindoles and 2,3-dibromo/2,3-dichloroindoles by using 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) and 1,3-dichloro-5,5-dimethylhydantoin (DCDMH) were developed. Using 1,4-dioxane as the solvent, a variety of indoles, treated with 0.55 equiv DBDMH/DCDMH, afford the corresponding 3-bromo/3-chloroindoles selectively in 82-99% yield. In 1,2-dichloroethane (DCE), a series of 2,3-dichloro/2,3-dibromoindoles were selectively obtained in 84-95% yield by treating with DBDMH/DCDMH. All the processes do not need extra catalysts, dry solvents, or harsh reaction conditions.

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death. In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematological tumors. 71 has been taken into phase 1 clinical trials in patients with multiple myeloma and solid tumors.

4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.